Clinical Trial Update: Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase II trial of Abraxane, Avastin (bevacizumab), and carboplatin in triple-negative metastatic breast cancer completed; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Avastin (bevacizumab)
• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: Duke University | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-02-18